Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-081 in EGFR exon 20 insertion-mutant advanced NSCLC
NL-OMON56206Phase 2Recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) and bronchial carcinoma (6 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 10 more. Started Jun 2020; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON56206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56206.